biotech
Hearing drug failure puts biotech on brink
March 16, 2018Medical Communications, Research and Development Auris, biotech, drugs, pharma, pharmaceutical
Biotechs with few products in the portfolio are always at a risk should results come back flat, it often leads …
Solid Biosciences rocked by clinical hold, shareholders flee
March 15, 2018Research and Development Solid Biosciences, biotech, drugs, pharma, pharmaceutical
Solid Biosciences raised more than a few eyebrows when it only revealed a partial hold from the FDA stalling its …
Fat-fighting pharma business files for bankruptcy
March 15, 2018Sales and Marketing Contrave, biotech, drugs, orexigen, pharma, pharmaceutical
Orexigen Therapeutics, a biotech that was one of a wave of companies bringing through weight-loss pills, has announced that it …
Andrew Witty takes on a new CEO position
March 15, 2018Medical Communications Andrew Witty, GSK, Optum, UnitedHealth, biotech, drugs, pharma, pharmaceutical
Andrew Witty, who made his name working his way up the ranks at GSK to become its CEO, has revealed …
Top 5 Reasons Why You Should Attend Veeva R&D Summit, Europe
March 15, 2018Medical Communications biotech, drugs, pharma, pharmaceutical, veeva
Veeva R&D Summit, Europe is an annual gathering of pharma, biotech and medical devices professionals in clinical, regulatory, quality, and …
Takeda’s CFO departs forcing company to act
March 14, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Takeda, biotech, drugs, pharma, pharmaceutical
Takeda has announced that its Chief Financial Officer, James Kehoe, has decided to move on from the company to take …
Hammond suggests NHS may receive cash boost
March 14, 2018Medical Communications, Research and Development Autumn Budget, NHS, UK, biotech, drugs, pharma, pharmaceutical
The pressures on the NHS over the winter months exposed serious cracks in the service, with issues regarding underfunding, struggles …
World’s first synthetic, non-biologic vaccine developed
March 14, 2018Research and Development Vaccine, biotech, drugs, influenza, pharma, pharmaceutical
One of the major challenges in delivering vaccinations to all parts of the globe is the need to keep the …
AbbVie secures further strong results for potential blockbuster
March 13, 2018Research and Development AbbVie, biotech, drugs, elagolix, pharma, pharmaceutical
AbbVie’s elagolix has been slated as a blockbuster-in-the-making by analysts predicting big things for the potential treatment for uterine fibroids …
Adaxis-AZ immunotherapy combo hit by clinical hold after death
March 13, 2018Manufacturing and Production, Research and Development Adaxis, AstraZeneca, Imfinzi, biotech, drugs, immunotherapy, pharma, pharmaceutical
Adaxis and AstraZeneca announced that they had agreed a combination program for axalimogene filolisbac and Imfinzi, respectively, back in 2014 …
Novartis reshuffle begins under new CEO
March 13, 2018Manufacturing and Production, Medical Communications Novartis, biotech, digital, drugs, pharma, pharmaceutical
It’s a common strategy that newly appointed CEOs will try to change the direction of the company via rejigging leadership …
Pfizer begins sell-off, shedding CNS drug to Biogen for $590m
March 13, 2018Manufacturing and Production, Sales and Marketing Biogen, CNS, Pfizer, biotech, drugs, pharma, pharmaceutical
Pfizer’s decision to back out of the neuroscience space was a strategic move that send shudders through the entire industry, …
Study identifies five kinds of diabetes, potentially changing treatment
March 2, 2018Medical Communications, Research and Development biotech, diabetes, drugs, pharma, pharmaceutical
A decade-long study has unearthed findings that could entirely change how people living with diabetes are treated, after the classic …
Novartis forms a Pear to develop mobile therapies
March 2, 2018Medical Communications, Research and Development Novartis, Pear Therapeutics, biotech, drugs, pharma, pharmaceutical
Novartis has announced an agreement between Pear Therapeutics and itself to develop two digital therapeutics, one in schizophrenia and one …
Merck/Pfizer’s Bavencio wins slight reprieve after NICE nod
March 1, 2018Medical Communications, Sales and Marketing Bavencio, Merck, Pfizer, biotech, drugs, pharma, pharmaceutical
Just two weeks ago, Merck KGaA and Pfizer were hit with a major setback for their PD-L1 immunotherapy, Bavencio, after …
Latest content
